Mandate

Vinge advises Xspray Pharma in connection with its listing on Nasdaq Stockholm

April 01, 2020

Vinge advises Xspray Pharma AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm. The prospectus was published on 23 March 2020 and the trading on Nasdaq Stockholm commenced on 27 March 2020.

Xspray Pharma is a product development company that develops improved and generic versions of marketed drugs, primarily protein kinase inhibitors for the treatment of cancer. Xspray has multiple product candidates in clinical development.

Vinge’s team has primarily consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Joel Magnusson, Maria Schultzberg, Stojan Arnerstål and Henrik Wastenson.

Related news

Sanctions update December (part 2)

Further to our previous sanctions newsletters we herewith inform about recent sanctions developments, following the Council’s adoption of the ninth sanction package on 16 December 2022, and an agreement as to a price cap on Russian gas.
December 30, 2022

COP27 – one step closer to climate justice

COP27 was concluded on 18 November 2022 after two weeks of negotiations in Sharm El Sheikh in Egypt with the presence of leaders and representatives from 190 countries. The 1.5 °C target was a priority item on the agenda ahead of COP27, along with the efforts to support developing countries, which are particularly vulnerable to the effects of climate change. Amongst the EU’s top priorities ahead of the conference were to accelerate the phase out of coal, as well as to abolish inefficient fossil fuel subsidies.
December 19, 2022

Sanctions update December 2022

Further to our previous sanctions newsletters we herewith inform about recent sanctions developments as follows.
December 14, 2022